Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients - study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study.

Journal: Pleura and peritoneum
Published Date: Jun 12, 2018

Abstract

BACKGROUND: Peritoneal metastasis (PM) is the second most common site of recurrence in colon cancer (CC) patients and accounts for approximately one-third of all recurrences. Patients with T4 or intraperitoneal perforated colon cancers have an increased risk of developing PM, and since manifest PM is difficult to treat, high-risk patients should be offered prophylactic treatment. Here, we propose a study of adjuvant oxaliplatin administered as pressurized intraperitoneal aerosol chemotherapy (PIPAC OX) in patients with high-risk colon cancer (T4, perforated tumors, ovarian metastasis).

Authors

  • Martin Graversen
    Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Oncology, Odense University Hospital, Odense C 5000, Denmark.
  • Sönke Detlefsen
    Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Claus Fristrup
    Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Per Pfeiffer
    Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Michael Bau Mortensen
    Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), HPB and Upper GI Section, Department of Surgery, Odense University Hospital, Odense, Denmark.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals